Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome

被引:0
|
作者
Paterakis, Thomas S.
Diamanti-Kandarakis, Evanthia [1 ,2 ]
机构
[1] Univ Athens, Sotiria Hosp, Med Sch, Mesogeion 152, Athens, Greece
[2] Univ Athens, Sch Med, GR-14578 Athens, Greece
来源
CURRENT OBESITY REPORTS | 2014年 / 3卷 / 04期
关键词
Polycystic ovary syndrome; Cardiometabolic syndrome; Cardiovascular disease; Cardiometabolic risk markers;
D O I
10.1007/s13679-014-0127-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Women with polycystic ovary syndrome (PCOS), the most common endocrine disorder among women of reproductive age, exhibit an adverse cardiovascular risk profile characteristic of the cardiometabolic syndrome. These women, compared with age- and body mass index-matched women without PCOS, appear to present a higher risk of insulin resistance, glucose intolerance, and dyslipidemia, and possibly a higher rate of type 2 diabetes mellitus and cardiovascular disease. However, despite the presence of cardiovascular risk factors and increased surrogate markers of cardiovascular disease, it is unclear whether they have accelerated atherosclerosis and greater mortality, the latter mainly because of a lack of endpoint studies. This article addresses, summarizes, and discusses salient data from the existing literature, including gaps and uncertainties, aspects, and mechanisms related to the spectrum of adverse cardiometabolic profile factors in women with PCOS.
引用
收藏
页码:377 / 386
页数:10
相关论文
共 50 条
  • [1] Aspects of Cardiometabolic Risk in Women with Polycystic Ovary Syndrome
    Thomas S. Paterakis
    Evanthia Diamanti-Kandarakis
    [J]. Current Obesity Reports, 2014, 3 (4) : 377 - 386
  • [2] Cardiometabolic Aspects of the Polycystic Ovary Syndrome
    Randeva, Harpal S.
    Tan, Bee K.
    Weickert, Martin O.
    Lois, Konstantinos
    Nestler, John E.
    Sattar, Naveed
    Lehnert, Hendrik
    [J]. ENDOCRINE REVIEWS, 2012, 33 (05) : 812 - 841
  • [3] Cardiometabolic risk in polycystic ovary syndrome
    Studen, Katica Bajuk
    Pfeifer, Marija
    [J]. ENDOCRINE CONNECTIONS, 2018, 7 (07): : R238 - +
  • [4] Cardiometabolic biomarkers in women with polycystic ovary syndrome
    van der Ham, Kim
    Louwers, Yvonne, V
    Laven, Joop S. E.
    [J]. FERTILITY AND STERILITY, 2022, 117 (05) : 887 - 896
  • [5] VISFATIN AS A POTENTIAL CARDIOMETABOLIC RISK FACTOR IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
    Koleva-Tyutyundzhieva, D.
    Ilieva-Gerova, M.
    Deneva, T.
    Nikolova, J.
    Orbetzova, M.
    [J]. ATHEROSCLEROSIS, 2023, 379 : S104 - S104
  • [6] Cardiometabolic risk in patients with polycystic ovary syndrome
    Ozegowska, Katarzyna
    Pawelczyk, Leszek
    [J]. GINEKOLOGIA POLSKA, 2015, 86 (11) : 840 - 848
  • [7] Cardiometabolic risk factors in polycystic ovary syndrome
    Mehrabian, Ferdous
    Keramatian, Kasra
    Kelishadi, Roya
    [J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2012, 28 (02) : 339 - 344
  • [8] Does body weight affect cardiometabolic risk in women with polycystic ovary syndrome?
    Dokras, Anuja
    [J]. FERTILITY AND STERILITY, 2019, 111 (01) : 56 - 57
  • [9] Impact of Lisinopril on Cardiometabolic Risk Factors in Sisters of Women With Polycystic Ovary Syndrome
    Krysiak, Robert
    Kowalcze, Karolina
    Okopien, Boguslaw
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 63 (09): : 1045 - 1052
  • [10] The Impact of Atorvastatin on Cardiometabolic Risk Factors in Sisters of Women with Polycystic Ovary Syndrome
    Krysiak, Robert
    Kowalcze, Karolina
    Okopien, Boguslaw
    [J]. PHARMACOLOGY, 2023, 108 (05) : 451 - 459